HIV

Luciferase reporter cell lines are invaluable tools in molecular biology, often utilized for studying gene expression, signaling pathways, and drug screening. Among these, the Jurkat cell line, derived from human T lymphocyte cells, has gained prominence due to its ease of transfection and robust responsiveness to stimuli. The addition of a luciferase reporter system to Jurkat cells allows researchers to quantitatively measure gene expression in real-time using luminescence.

What is the Jurkat Cell Line?

The Jurkat cell line was originally established in 1984 from the peripheral blood of a 14-year-old boy with acute T cell leukemia. This immortalized cell line retains many of the characteristics of normal T cells, making it an ideal model for studying T cell activation, differentiation, and signaling. Its capacity for rapid growth and proliferation under controlled laboratory conditions enhances its use in research.

The Role of Luciferase in Research

Luciferase is an enzyme that catalyzes a reaction producing light, which can be quantified. When Jurkat cells are engineered to express a luciferase gene under the control of a specific promoter, researchers can monitor the activity of that promoter in response to various stimuli. For instance, the activation of T cell receptors or other signaling pathways can be assessed by measuring the luminescent output, providing insights into cellular processes.

Applications of Jurkat Luciferase Reporter Cell Lines

Gene Expression Studies: By linking luciferase activity to specific gene promoters, scientists can assess how different factors affect gene expression in T cells.
Drug Screening: These cell lines can be employed in high-throughput screening to evaluate the effects of pharmaceutical compounds on T cell activation and proliferation.
Immunology Research: Jurkat cells are utilized to study immune responses, making luciferase reporter lines essential for understanding T cell biology and therapeutic interventions.
Signal Transduction Pathways: Researchers can study various signaling cascades by introducing reporters controlled by specific response elements, allowing for the dynamic analysis of cellular signaling.

Conclusion

The Luciferase Reporter Cell Line - Jurkat represents a powerful and versatile tool in the field of molecular biology and immunology. Its ability to provide real-time quantification of gene expression and cellular responses enables researchers to unravel complex biological systems, paving the way for advancements in therapeutic strategies and biomedical research. As the understanding of T cell biology continues to evolve, luciferase reporter Jurkat cells will undoubtedly play a crucial role in future discoveries.

Courses tagged with "HIV"

Webinar: Let’s talk about sex – raising awareness of STIs among adolescents and young adults in 2025

The aim of this webinar is to raise awareness of STIs among adolescents and youth through the sharing of successful initiatives.

Dates and duration: 2 April 2025, 15:00-16:30 CET

Audience: The webinar is designed for EU/EEA (i) public health practitioners and health care workers at national, regional and local levels, (ii) civil society actors and (iii) education providers.

Objectives: After completing this webinar, the participants should be able to:

Articulate which messages about safe sex resonate with young people today
Indicate new channels of communication with adolescents in 2025 and in the future
Identify actions that they could consider taking to increase awareness of STIs among adolescents and young adults in their context

Participation: Please register here to receive your Zoom link to attend this webinar.

Category: 2025 catalogue

Webinar: Building successful partnerships with civil society and clinical services for STI prevention among MSM at high risk of STIs

The aim of this webinar is to strengthen country capacity to prevent and control gonorrhoea, syphilis, and chlamydia among MSM at high risk for STIs through the sharing of successful initiatives between public health authorities, clinicians and civil society actors.

Dates and duration: 26 March 2025, 15:00-16:30 CET

Audience: Public health practitioners and healthcare providers at national, regional and local levels

Objectives: After completing this webinar, the participants should be able to:

Be able to articulate the importance of partnerships between public health, civil society, and clinical services in preventing STIs and improving sexual health among high-risk MSM
Have identified actions that they could consider taking to establish/strengthen regular cooperation with civil society actors and clinicians in their context/settings

Participation: Please register here to receive your Zoom link to attend this webinar.

Category: 2025 catalogue

Face-to-face workshop: Using HIV modelling tools to estimate HIV incidence, prevalence and the first 95% target

The overall aim of this face-to-face workshop organised by ECDC, EACS and CHIP is to train participants with the skills and knowledge to effectively use HIV Modelling Tools, including data preparation, tool navigation, accuracy assurance, handling of multiple imputations, and interpretation of results to support informed decision-making and alignment with global targets for ending the AIDS epidemic by 2030.

⏳ Duration: 2 days

📌Location: EACS (Brussels, Belgium)

👥 Audience: This workshop is aimed toward national representatives working in HIV surveillance (modelers, statisticians, data scientists, and epidemiologists) nominated by National Focal Points.

🔑 Participation: By invitation only.

🎯 Objectives: At the end of the workshop, participants should:

Have gained expertise in ECDC and/or UNAIDS HIV modelling tools, including the ability to successfully upload, map, and prepare diverse data types, with an understanding of defining variables related to migration, deaths, and previous positive cases.
Have a comprehensive understanding of multiple imputations for adjusting missing data, including selection of appropriate methods and review of diagnostic measures to assess the efficacy of the imputation process
Have obtained national HIV estimations with adjustments for missing data and reporting delay, migration, and previous positives.
Have developed competences to interpret results and use imputed data for informed decision-making.

Category: 2025 catalogue

ECDC HIV Modelling Tool

The ECDC HIV Modelling Tool is a tool developed by ECDC in collaboration with international partners to provide estimates of the number of people living with HIV, including those not yet diagnosed. The tool can also estimate the annual number of new HIV infections, the average time between infection and diagnosis, and the number of people in need of treatment according to CD4 counts. To achieve all of this, the tool needs only routinely collected HIV surveillance data. Nearly all countries in the European region report annual HIV and AIDS diagnoses to the TESSy database hosted at ECDC.

Given that almost all countries in the European region annually report HIV and AIDS diagnoses to the TESSy database hosted at ECDC, the materials provided in this module aim to guide users through precise steps in preparing the data. This guidance ensures that the HIV Modelling Tool runs smoothly, ultimately providing accurate estimates for each country.

Duration: Self-paced

Audience: The training is designed for professionals in HIV surveillance specialist, including modelers, statisticians, data scientists, and epidemiologists actively working in the field of HIV.

Objectives: After completing this training, the participants will be able to:

Prepare diverse data types (case-based, aggregated) for the ECDC HIV Modelling Tool. This includes adept navigation of the tool's interface, successful data uploads, and effective mapping, with a focus on nuances such as defining migrant variables.
Apply quality assurance techniques for ensuring the accuracy and reliability of data uploaded to the tool.
Understand the multiple imputations for missing data adjustment.

Participation: This training material will be open without enrolment.

Webinar: Improving testing for HIV and related co-infections in general practice

The overall aim of this webinar organised by ECDC, the European Clinical AIDS Society (EACS) and the Centre of Excellence for Health, Immunity and Infections (CHIP) is to increase general practitioner and nurse knowledge and awareness of integrated testing, including indicato-guided testing, why this is important, and what can be done to increase testing for HIV and related co-infections in practice.

Date: 21 March 2023, 15:00 CET

Duration: 60 minutes

Audience: This webinar is aimed at (i) nurses and (ii) physicians working in general practices in EU/EEA countries.

Objectives: At the end of the webinar, participants should:

Have an increased understanding of common HIV indicator conditions and co-infections, such a viral hepatitis, STIs and tuberculosis;
Have an increased knowledge of existing integrated testing guidance, including indicator-guided testing, and why this is important; and
Understand how to implement indicator-guided testing in practice.

Introduction to the 2023 ECDC-EMCDDA guidance on preventing and controlling infectious diseases among people who inject drugs

The webinar introduces the updated ECDC-European Monitoring Centre for Drugs and Drug Addiction (ECDC-EMCDDA) guidance on preventing and controlling infectious diseases among people who inject drugs.

Dates and duration: 13 March 2024, 15:00-16:00 CET

Audience: The webinar is designed for (i) policymakers and public health/social programmers responsible for developing national strategies, policies, and programmes, (ii) public health and health professionals working with people who inject drugs, and (iii) representatives from civil society organisations and the community.

Objectives: After completing this webinar, the participants should be able to:

Describe the six key intervention areas to prevent and control infectious diseases among people who inject drugs according to the updated ECDC-EMCDDA guidance.
Explain why interventions to prevent and control infectious diseases among people who inject drugs should be delivered in line with principles for prevention and service provision.
Describe some models of good practice for community-based testing, linkage to care and adherence to treatment for hepatitis B and C, HIV, and tuberculosis in the EU/EEA.

Participation: Please register here to receive your Zoom link to attend this webinar.

Webinar: Stigma: what you as a healthcare provider can do to address it

The overall aim of this online webinar organised by ECDC, European Clinical AIDS Society (EACS) and the Centre of Excellence for Health, Immunity and Infections (CHIP) is to increase general practitioner and nurse knowledge and awareness of what stigma is, how it impacts patient health in the areas of HIV, viral hepatitis and sexually transmitted infections, and how it can be addressed in general practice.

Date: 14 June 2023, 15:00 CEST

Duration: 60 minutes

Audience: This webinar is aimed toward (i) nurses and (ii) physicians working in general practices in EU/EEA countries.

Participation: To participate in this webinar, please use this Zoom registration link. You will then be sent a calendar invite with more information on how to join the webinar.

ECDC capacity building related to Sustainable Development Goal 3.3

Back to all items tagged with "HIV"